SCHEMBL6707897

SCHEMBL6707897

Cc1cc(NC(=O)c2c(C)n[nH]c2C)ccc1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 7/20 0.53
KDR P35968 5/20 0.53
HTT P42858 3/20 0.48
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
P2RX7 Q99572 2/20 0.41
MAPT P10636 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
LRRK2 Q5S007 2/20 0.40
TTR P02766 1/20 0.39
XDH P47989 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6707197 0.82 AHR (0.54) FLT1KDRHTTLMNASMN1; SMN2
SCHEMBL6712450 0.81 EPAS1 (0.47) FLT1KDRHTTLMNASMN1; SMN2
SCHEMBL7968338 0.79 SLC11A2 (0.44) HTTALDH1A1MEN1NPC1RAB9A
SCHEMBL6709302 0.78 FLT1 (0.51) FLT1KDRHTTLMNASMN1; SMN2
SCHEMBL6710587 0.78 FLT1 (0.64) FLT1KDRHTTLMNASMN1; SMN2
SCHEMBL6707922 0.75 KIF11 (0.48) HTTLMNAALDH1A1POLBMEN1
SCHEMBL4631791 0.74 AURKA (0.51) LMNASMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL23974251 0.73 MAP2K1 (0.54) KDRHTTLMNASMN1; SMN2ALDH1A1
SCHEMBL6707284 0.72 FLT1 (0.51) FLT1KDRHTTLMNASMN1; SMN2
SCHEMBL6709083 0.72 ALDH1A1 (0.60) HTTSMN1; SMN2ALDH1A1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders SUGEN, INC. 2004-05-27 US disclosed
US-6649635-B2 For therapy of cancer SUGEN, INC. 2003-11-18 US disclosed
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders MCMAHON GERALD (US) 2002-05-30 US disclosed
EP-1012150-A4 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN INC (US) 2002-05-29 EP disclosed
US-6316479-B1 ANTICANCER AGENTS SUGEN, INC. 2001-11-13 US disclosed
EP-1012150-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS Sugen, Inc. (US) 2000-06-28 EP disclosed
WO-1998052944-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN, INC. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC FLT1 727/4885KDR 633/4885HTT 1790/4885
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC FLT1 727/4885KDR 633/4885HTT 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.